

ASH 2025

67th ASH Annual Meeting and Exposition

December 6–9, 2025

Orlando, United States



TOP ABSTRACTS

To help navigate the exciting content being presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in multiple myeloma and other plasma cell dyscrasias.

ASH 2025: Top abstracts in multiple myeloma

December 6–9, 2025

Oral presentations: Saturday, December 6

Abstract	Title	Presenter	Time (EST)
92 View	Earlier use of ciltacabtagene autoleucel (cilta-cel) is associated with better immune fitness and stronger immune effects as shown by correlative analysis of peripheral blood and the bone marrow tumor microenvironment (TME) from the CARTITUDE-4 study	Samir Parekh	09:45–10:00
93 View	Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma	Doris Hansen	10:00–10:15
94 View	Long-term progression-free survival benefit with ciltacabtagene autoleucel in standard-risk relapsed / refractory multiple myeloma	Luciano Costa	10:15–10:30
97 View	Minimal residual disease dynamics in post-transplant patients with newly diagnosed multiple myeloma who received daratumumab plus lenalidomide versus lenalidomide alone as maintenance therapy in the AURIGA study	Alfred Chung	09:30–09:45
99 View	Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma (NDMM) – interim results from the randomized phase III COBRA trial	Dominik Dytfeld	10:00–10:15
100 View	Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial	Attaya Suvannasankha	10:15–10:30
101 View	Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial	Niels van de Donk	10:30–10:45
102 View	Initial phase 1b/2 study results with sonrotoclax (BGB-11417) in combination with carfilzomib and dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma	Hang Quach	10:45–11:00
365 View	Immune biomarkers of increased risk of infection in multiple myeloma (MM)	Aintzane Zabaleta	17:00–17:15
368 View	Sustained minimal residual disease (sMRD) negativity in transplant ineligible newly diagnosed multiple myeloma treated with isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus Isa-Rd: 12-24-month data from the phase 3 BENEFIT trial (IFM 2020-05)	Arthur Bobin	16:15–16:30
370 View	Role of bortezomib maintenance therapy in the anti-CD38 antibody era: Interim analysis results of a randomized phase III study for transplant-ineligible newly diagnosed multiple myeloma (JCOG1911/B-DASH study)	Tomotaka Suzuki	16:45–17:00

Oral presentations: Sunday, December 7

Abstract	Title	Presenter	Time (EST)
494 View	Combined assessment of circulating tumor cells (CTCs) and measurable residual disease (MRD) for dynamic risk assessment of patients (Pts) with multiple myeloma (MM)	Bruno Paiva	09:45–10:00
578 View	Ending the undetermined significance of monoclonal gammopathies (MGUS): First results of the NoMoreMGUS study	Bruno Paiva	12:15–12:30
698 View	Efficacy and safety of talquetamab + teclistamab in patients with relapsed/refractory multiple myeloma and extramedullary disease: Updated phase 2 results from the RedirecTT-1 study with extended follow-up	Saad Usmani	16:45–17:00
701 View	Safety and efficacy of talquetamab + teclistamab in patients with relapsed/refractory multiple myeloma from phase 1b of RedirecTT-1: Results with an extended median follow-up of 3 years	María-Victoria Mateos	17:30–17:45

Oral presentations: Monday, December 8

Abstract	Title	Presenter	Time (EST)
916 View	S100A8/A9 drives T cell exhaustion and compromises the therapeutic efficacy of bispecific antibodies in multiple myeloma	Adolfo Aleman	15:30–15:45
1033 View	The impact of Duffy genotype on progression-free survival (PFS) with lenalidomide, bortezomib, and dexamethasone (RVd) alone or RVd plus autologous stem cell transplantation (ASCT) and continuous R maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM): Updated subgroup analysis of the phase 3 DETERMINATION trial	Lauren Merz	16:30–16:45
1034 View	Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality	Surbhi Sidana	16:45–17:00
1035 View	Outcomes of stem cell boost (SCB) versus supportive care alone for prolonged cytopenias after chimeric antigen receptor T cell therapy (CAR-T) in relapsed/refractory multiple myeloma (RRMM): A multi-center real-world analysis	Cindy Varga	17:00–17:15
1037 View	Redefining function high-risk (FHR) multiple myeloma (MM) in the context of upfront quadruplet (QUAD) therapy and autologous stem cell transplantation (ASCT)	Luciano Costa	17:30–17:45

Oral presentations: Tuesday, December 9

Abstract	Title	Presenter	Time (EST)
LBA-1 View	Minimal residual disease (MRD)-negative outcomes following a novel, <i>in vivo</i> gene therapy generating anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): Preliminary results from inMMycAR, the first-in-human phase 1 study of KLN-1010	Phoebe Joy Ho	07:30–07:45
LBA-6 View	Phase 3 randomized study of teclistamab plus daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd/DVd) in patients (pts) with relapsed refractory multiple myeloma (RRMM): Results of MajesTEC-3	María-Victoria Mateos	08:45–09:00

Posters

Abstract	Title	Presenter	Date and time (EST)
2253 View	A clinical overview of infection in patients receiving elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) for newly diagnosed multiple myeloma in the MagnetisMM-6 trial	Ja Min Byun	Saturday, December 6, 17:30–19:30
2258 View	Randomized comparison between isatuximab-Rd versus Rd induction, followed by isa-R versus R maintenance in very elderly patients with NDMM: Efficacy data on MRD after induction (AGMT-MM04 Trial)	Heinz Ludwig	Saturday, December 6, 17:30–19:30
2262 View	Long-term responders from the phase 3 DREAMM-7 study of belantamab mafodotin plus bortezomib and dexamethasone vs daratumumab plus bortezomib and dexamethasone in relapsed/refractory multiple myeloma	Vania Hungria	Saturday, December 6, 17:30–19:30
2263 View	Health-related quality of life (HRQoL) in patients with newly diagnosed multiple myeloma (NDMM) eligible for transplantation and treated with isatuximab, lenalidomide, bortezomib, and dexamethasone (Isa-RVd) versus RVd alone: Results from Part 1 of the GMMG-HD7 study	Elias K. Mai	Saturday, December 6, 17:30–19:30
2264 View	Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the phase 3 DREAMM-8 study	Suzanne Trudel	Saturday, December 6, 17:30–19:30

2265 View	Patients with relapsed/refractory multiple myeloma who achieved sustained minimal residual disease negativity in the DREAMM-7 trial	María-Victoria Mateos	Saturday, December 6, 17:30–19:30
4069 View	Identifying high-risk profiles and adverse prognoses in relapsed/refractory multiple myeloma treated with bispecific antibodies: A real-world analysis of 943 treatment initiations	Saurabh Zanwar	Sunday, December 7, 18:00–20:00
4029 View	Health-related quality of life with belantamab mafodotin in patients with relapsed or refractory multiple myeloma (RRMM): An exploratory analysis of overall quality of life in DREAMM-7	Sagar Lonial	Sunday, December 7, 18:00–20:00
4039 View	Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND)	Matthew Rees	Sunday, December 7, 18:00–20:00
4044 View	Home administration of isatuximab subcutaneous by on-body injector in relapsed/refractory multiple myeloma in the phase 3 IRAKLIA study	María-Victoria Mateos	Sunday, December 7, 18:00–20:00
5820 View	Functional high-risk relapsed/refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): DREAMM-7 and DREAMM-8 subgroup analysis	María-Victoria Mateos	Monday, December 8, 18:00–20:00
5823 View	Patient-reported outcomes from DREAMM-7 and DREAMM-8 using the EQ-5D-3L, patient global impression of severity, and patient global impression of change	Suzanne Trudel	Monday, December 8, 18:00–20:00



#ASH25

Follow us on X to keep up to date
with the latest from the congress

@MM_Hub

 **MultipleMyelomaHub**

Brought to you by

